Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 pos KIT V560del |
Therapy | Imatinib + unspecified PD-L1 antibody |
Indication/Tumor Type | gastrointestinal stromal tumor |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 pos KIT V560del | gastrointestinal stromal tumor | sensitive | Imatinib + unspecified PD-L1 antibody | Preclinical | Actionable | In a preclinical study, the combination of Gleevec (imatinib) and a PD-L1 antibody resulted in a greater decrease in tumor weight and increased apoptotic activity in a gastrointestinal stromal tumor mouse model harboring KIT V558del (corresponds to human KIT V560del) and expressing PD-L1 compared to Gleevec (imatinib) and control (PMID: 27470968). | 27470968 |
PubMed Id | Reference Title | Details |
---|---|---|
(27470968) | PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. | Full reference... |